5 shares of pharmaceutical companies working on a vaccine against the coronavirus
|Pharmaceutical company||Current market price||Vaccine|
|Dr Reddy’s laboratories||4,903 rupees||Sputnik V|
|Wockhardt||419 rupees||Sputnik V|
|Panacea Biotec||312 rupees||Sputnik V|
|Cadila Health||552 rupees||ZyCov-D|
|Cipla||Rs 944 76.||Moderna|
Dr Reddy’s laboratories
The Dr. Reddy’s Laboratories share is in the spotlight today as the pharmaceutical giant announced that it had reached an agreement to sell its rights to an anti-cancer drug to Citius Pharmaceuticals in the United States. Apart from that, the company said it will launch the India-made Sputnik V vaccine in India between September and October of this year.
If the Sputnik V vaccine gets wide approval, it will benefit the company in the medium term, especially if it becomes a major exporter this year.
Despite the fact that the price pressure in US markets has eased, the new administration in the US has a history of falling drug prices. If this happened regularly, export margins could suffer. Due to the low margins in Q1-FY22, the price risk resurfaced.
Dr. Reddy’s Laboratories exercised stock options and distributed 14,284 fully paid shares worth Rs 7.28 crore to various workers. According to a regulatory file, the ESOP consists of 6,774 shares of Rs 5 each under the stock option program for employees of Dr. Reddy and 7,510 shares of Rs 5 each under the ADR stock option program.
The stock returned 86.74% over three years, compared to 48.94% for the Nifty 100. Over a three-year period, the stock returned 86.74%, compared to 36.87% for Nifty. Pharma.
Wockhardt previously announced that it has entered into an agreement for the manufacture and supply of the Sputnik V / Sputnik Light vaccine against Covid-19 with Enso Healthcare DMCC (Enso), a company based in Dubai, United Arab Emirates, and Human Vaccine LLC (HV ), a wholly-owned subsidiary of the Sovereign Fund of the Russian Federation (RDIF).
The single-dose Sputnik Light Covid-19 vaccine is expected to be launched soon in India, according to Russian diplomat Nikolay Kudashev, as quoted by the ANI news agency.
Only 4.14% of trading sessions over the past 16 years have seen intraday declines of more than 5%. During the fiscal year ended March 31, 2021, the company achieved an ROE of 20.31%, exceeding its five-year average of -2.56%. The increase in the company’s QoQ revenue was 34.67%, the highest of the previous three years. Over a three-year period, the stock returned -37.79%, while Nifty Pharma returned 36.87% to investors.
Panacea Biotec shares jumped 5.74% to Rs.311.50 after the company announced the first shipment of 1 million doses of the second component of Panacea Biotec’s Russian coronavirus vaccine Sputnik V for sale in India .
This is the first batch of the company’s second component, which is manufactured and supplied in India. Panacea Biotec’s advanced vaccine manufacturing plant in Himachal Pradesh produced the doses for the second component of Sputnik V.
The stock returned 20.82% over three years, compared to 39.62% for the Nifty Smallcap 100. Over a three-year period, the stock returned 20.82%, while Nifty Pharma returned 36.87 % to investors.
Moderna vaccine will be available as a ready-to-use injectable vaccine. Once opened, it can be stored for seven months at a specified temperature and for 30 days at room temperature.
Nevertheless, the monetary director of the company admitted that there was currently “nothing conclusive”.
Moderna and the Indian government are working together to determine vaccine compensation points. 14 days after the first dosage, the Moderna vaccine had an efficacy rate of 94.1%.
Cipla’s web revenue grew 24% year-over-year in the second quarter of 2021. The company’s revenue also grew 27% year-over-year, thanks to an increase in demand for Covid-19 drugs following the second wave of the pandemic.
With Remdesivir, Favipiravir and Toclizumab, the company has been aggressive in building a Covid care portfolio. As the cases of covid increase again, their influence should be noticeable until the first half of FY22. The company has the option to continue because one of its main advantages is its cheap price.
A health ministry official said Cadila Healthcare, a pharmaceutical company, would start providing a coronavirus vaccine to children aged 12 to 17 in October.
Ahead of the distribution of the Zydus Cadila vaccine in October, details of the Covid-19 vaccination for young people aged 12 to 17, including priority for those with health problems, will be announced, according to reports.
According to the Department of Biotechnology (DBT), ZyCoV-D is the world’s first DNA-based coronavirus vaccine, which, when administered, creates the spike protein of the SARS-CoV-2 virus and stimulates an immune response that aids in disease prevention and viral clearance.
The stock returned 30.73% over three years, compared to 48.94% for the Nifty 100.
Investing in stocks presents a risk of financial loss. Investors should therefore exercise caution. Greynium Information Technologies, the author and the brokerage houses are not responsible for any losses caused as a result of decisions based on the article. The above article is for informational purposes only and is taken from Sharekhan’s brokerage report.